Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer.
about
Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Financial consequences of a pa ...... ve non-small-cell lung cancer.
@en
Financial consequences of a pa ...... ve non-small-cell lung cancer.
@nl
type
label
Financial consequences of a pa ...... ve non-small-cell lung cancer.
@en
Financial consequences of a pa ...... ve non-small-cell lung cancer.
@nl
prefLabel
Financial consequences of a pa ...... ve non-small-cell lung cancer.
@en
Financial consequences of a pa ...... ve non-small-cell lung cancer.
@nl
P2093
P2860
P1476
Financial consequences of a pa ...... ve non-small-cell lung cancer.
@en
P2093
Ana Clopes
Antoni Gilabert
Candela Calle
Josep R Germà
Luis A Cordero
Montse Gasol
Ramón Mora
Ricard Crespo
Rosana Cajal
P2860
P356
10.1080/13696998.2016.1215991
P407
P577
2016-07-21T00:00:00Z